At #MauiDerm2026, Linda Stein Gold, MD, shared key insights on emerging psoriasis therapies—and why early recognition of psoriatic arthritis matters. From PsA red flags to navigating IL-23s, IL-17s & TYK2s, watch the full interview:

JAK inhibitors are the biggest hair loss advance in 2 years, says Benjamin Ungar, MD @IcahnMountSinai. He breaks down safety data, where oral minoxidil fits, and why JAKs are now first-line for severe #alopeciaareata. #MauiDerm2026

Rosacea looks different at every age. Hilary Baldwin, MD, @sunydownstate walks through a single patient's journey from red-cheeked toddler to rhinophyma and ocular disease in older age, and why treatment may change at every stage. #MauiDerm2026

At #MauiDerm2026, Ashfaq Marghoob, MD, emphasized reassurance in pediatric dermoscopy—highlighting benign scalp, palm/sole, and nail patterns in children. He also shared optimism about AI improving melanoma screening.

Watch/read more:

At #MauiDerm2026, Ashfaq Marghoob, MD, shared key dermoscopy pearls for special sites—face, palms, soles, and nails—highlighting microanatomy differences that shape melanoma detection.

Read more:

ICYMI: Eingun James Song, MD, discusses DLQI, pruritus, and advances in non-steroidal topicals like tapinarof & roflumilast at #MauiDerm2026.
🔗

Eingun James Song, MD, discusses DLQI, pruritus, and advances in non-steroidal topicals like tapinarof & roflumilast at #MauiDerm2026.
🔗 www.hcplive.com/view...

New phase 3 OptIMMize-1 data presented at #MauiDerm2026 suggest risankizumab remained effective and well tolerated through 52 weeks in children and adolescents with moderate-to-severe psoriasis.
🔗

HCPLive is headed to #MauiDerm2026 (@MauiDerm)!

Do you know which sessions to attend? Check out our highlights of key sessions, as our team will be on-site interviewing expert presenters in the #dermatology space.

View here:
www.hcplive.com/view...